CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $167.55 at close of the session on Tuesday, Feb 09, made a downturn move of -0.99% on its previous day’s price.
Looking at the stock we see that its previous close was $169.23 and the beta (5Y monthly) reads 2.31 with the day’s price range being $166.21 – 175.44. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, CRSP has a high of $220.2 and a low of $32.3. The company’s stock has gained about -13.55% over that past 30 days.
CRISPR Therapeutics AG has a market cap of $12.31 Billion and is expected to release its quarterly earnings report on Feb 10, 2021- Feb 15, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the CRSP stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$1.27, with the EPS growth for the year declined at -$5.02 for 2021 and -$5.32 for next year. These figures represent -5.29% and 0.06% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the CRSP stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 19 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 7 have rated the CRISPR Therapeutics AG (CRSP) stock as a Hold, while 10 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas 2 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the CRSP stock currently stands at 0, and the current price level is -6.83% off its SMA20 and 2.35% from its 50-day simple moving average. The RSI (14) is pointing at 47.33 while the volatility over the past week is 4.9% and jumps to 6.46% over the past one month. The beta value is 2.31, while the average true range (ATR) is currently pointing at 11.51. The average price target for the stock over the next 12 months is $146.56, with the estimates having a low of $45 and a high of $210. These price ends are -73.14% and +25.34% off the current price level respectively, although investors could be excited at the prospect of a -4.51% if the CRSP share price touches on the median price of $160.
Let’s briefly compare CRISPR Therapeutics AG (CRSP) stock to its peers. We find that current price change of -0.99% and +195.92% over the past 12 months for CRSP competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.78% in the last trading session and was -10.69% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.39% previous session, and was +4.06% up over the past year, while Gilead Sciences Inc (GILD) was also down -0.99% in the last session, while its price remained in the green at 195.92% over the same period. CRISPR Therapeutics AG has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.22. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.11% and -0.03%, respectively, at close of the trading.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Coming back to CRISPR Therapeutics AG (NASDAQ:CRSP), we note that the average 3-month trading volume was 1.87 Million, while that of the preceding 10-day period stands at 2.24 Million. Current shares outstanding are 75.13 Million.
According to data from Thomson Reuters, insiders hold 13.71% of the company’s shares while institutions hold 68.49%. The data shows that short shares as of January 14, 2021, stood at 3.64 Million at a short ratio of 1.4. This represents a 4.84% short interest in shares outstanding on January 14, 2021. Shares short rose in January from the previous month at 3.61 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +9.43% up in year-to-date price movement.